These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35559260)

  • 1. Cost-Effectiveness Analysis of Hepatic Arterial Infusion Chemotherapy of Infusional Fluorouracil, Leucovorin, and Oxaliplatin Versus Transarterial Chemoembolization in Patients With Large Unresectable Hepatocellular Carcinoma.
    Zhang H; Zeng X; Peng Y; Tan C; Wan X
    Front Pharmacol; 2022; 13():849189. PubMed ID: 35559260
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial.
    Li QJ; He MK; Chen HW; Fang WQ; Zhou YM; Xu L; Wei W; Zhang YJ; Guo Y; Guo RP; Chen MS; Shi M
    J Clin Oncol; 2022 Jan; 40(2):150-160. PubMed ID: 34648352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Analysis of Hepatic Arterial Chemotherapy for Advanced Hepatocellular Carcinoma in China: A Comparative Analysis of HAIC-FO and Sorafenib.
    Gao J; Liu S; Li SJ; Wang R; Meng ZH; Kong XS
    Med Sci Monit; 2024 Jul; 30():e944526. PubMed ID: 39033318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study.
    He MK; Le Y; Li QJ; Yu ZS; Li SH; Wei W; Guo RP; Shi M
    Chin J Cancer; 2017 Oct; 36(1):83. PubMed ID: 29061175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for unresectable hepatocellular carcinoma: A systematic review with meta-analysis.
    Si T; Huang Z; Khorsandi SE; Ma Y; Heaton N
    Front Bioeng Biotechnol; 2022; 10():1010824. PubMed ID: 36237208
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness analysis of transarterial chemoembolization combined with lenvatinib as the first-line treatment for advanced hepatocellular carcinoma.
    He Y; Lin W; Cai Z; Huang Y; You M; Lei M; Chen R
    Front Pharmacol; 2023; 14():1219694. PubMed ID: 37745079
    [No Abstract]   [Full Text] [Related]  

  • 7. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Sorafenib for Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization: Retrospective Subgroup Analysis of 2 Prospective Trials.
    Huang Y; Zhang L; He M; Lai Z; Bu X; Wen D; Li Q; Xu L; Wei W; Zhang Y; Zhou Z; Chen M; Guo R; Shi M; Kan A
    Technol Cancer Res Treat; 2022; 21():15330338221117389. PubMed ID: 36529949
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma.
    Huang J; Huang W; Zhan M; Guo Y; Liang L; Cai M; Lin L; He M; Lian H; Lu L; Zhu K
    J Hepatocell Carcinoma; 2021; 8():1445-1458. PubMed ID: 34858889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness Analysis of Hepatic Arterial Infusion of FOLFOX Combined Sorafenib for Advanced Hepatocellular Carcinoma With Portal Vein Invasion.
    Li M; Lin S; Wilson L; Huang P; Wang H; Lai S; Dong L; Xu X; Weng X
    Front Oncol; 2021; 11():562135. PubMed ID: 33767976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine kinase inhibitors, immune checkpoint inhibitors combined with hepatic arterial infusion of oxaliplatin and raltitrexed versus oxaliplatin, 5-fluorouracil and leucovorin for intermediate and advanced hepatocellular carcinoma: A retrospective study.
    Zang M; Hu X; Yuan G; Li R; Li W; Pang H; Li Q; Chen J
    Int Immunopharmacol; 2023 Dec; 125(Pt A):111019. PubMed ID: 37879230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion to Resectability Using Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma.
    Li B; Qiu J; Zheng Y; Shi Y; Zou R; He W; Yuan Y; Zhang Y; Wang C; Qiu Z; Li K; Zhong C; Yuan Y
    Ann Surg Open; 2021 Jun; 2(2):e057. PubMed ID: 37636551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of hepatic arterial infusion chemotherapy combined with transarterial embolization for unresectable hepatocellular carcinoma: A propensity score-matching cohort study.
    Guo W; Gao J; Zhuang W; Wu Z; Li B; Chen S
    JGH Open; 2020 Jun; 4(3):477-483. PubMed ID: 32514457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic Artery Infusion Chemotherapy Using Fluorouracil, Leucovorin, and Oxaliplatin versus Transarterial Chemoembolization as Initial Treatment for Locally Advanced Hepatocellular Carcinoma: A Propensity Score-Matching Analysis.
    Li S; Lyu N; Han X; Li J; Lai J; He M; Deng H; Shi M; Wang H; Zhao M
    J Vasc Interv Radiol; 2021 Sep; 32(9):1267-1276.e1. PubMed ID: 34166806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic Arterial Infusion Chemotherapy with Modified FOLFOX as an Alternative Treatment Option in Advanced Hepatocellular Carcinoma Patients with Failed or Unsuitability for Transarterial Chemoembolization.
    Hsu SJ; Xu X; Chen MP; Zhao ZY; Wang Y; Yin X; Zhang L; Ge NL; Chen Y; Wang YH; Luo JF; Ren ZG; Chen RX
    Acad Radiol; 2021 Nov; 28 Suppl 1():S157-S166. PubMed ID: 33653656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study on the efficacy and safety of transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for large unresectable hepatocellular carcinoma.
    Yang J; Shang X; Li J; Wei N
    J Gastrointest Oncol; 2024 Feb; 15(1):346-355. PubMed ID: 38482220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic arterial infusion chemotherapy with or without lenvatinib for unresectable cholangiocarcinoma: a single-center retrospective study.
    Wang Y; Wei Z; Zhang Z; Xu J; Wang Y; Chen Q; Zhang Y
    Hepat Oncol; 2023 Jun; 10(2):HEP49. PubMed ID: 37850031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of transcatheter arterial chemoembolization with or without sorafenib for the treatment of unresectable hepatocellular carcinoma.
    Zhao RC; Zhou J; Wei YG; Liu F; Chen KF; Li Q; Li B
    Hepatobiliary Pancreat Dis Int; 2017 Oct; 16(5):493-498. PubMed ID: 28992881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic arterial infusion chemotherapy for hepatocellular carcinoma refractory to transarterial chemoembolization: exploring the influence of prior transarterial chemoembolization and additional transarterial chemoembolization on survival outcomes.
    Hien PN; Chun HJ; Oh JS; Kim SH; Choi BG
    J Gastrointest Oncol; 2024 Apr; 15(2):721-729. PubMed ID: 38756625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis.
    Hu J; Bao Q; Cao G; Zhu X; Yang R; Ji X; Xu L; Zheng K; Li W; Xing B; Wang X
    Cardiovasc Intervent Radiol; 2020 Jul; 43(7):996-1005. PubMed ID: 31974744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of adding transarterial chemoembolisation to lenvatinib as first-line treatment for advanced hepatocellular carcinoma in China.
    Li W; Wan L
    BMJ Open; 2023 Sep; 13(9):e074245. PubMed ID: 37751954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.